Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
- PMID: 33007379
- DOI: 10.1016/j.annonc.2020.09.018
Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
Conflict of interest statement
Disclosure SD declares personal honoraria from AstraZeneca until 2018; travel and accommodation support from AstraZeneca, Pfizer, Roche, Pierre Fabre; research funding from AstraZeneca, Pfizer, Roche, Puma, Carrick, Lilly, Myriad, Orion, Amgen, Sanofi, MSD, Genomic Health, GE, BMS, Servier. TG has declared no conflicts of interest.
Comment on
-
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20. Ann Oncol. 2020. PMID: 32828825 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
